The BIMAR study aims to compare electrophysiological data measured with electroretinogram (ERG) and electroencephalogram (EEG) between a group of euthymic patients with bipolar disorder (BD) and a group of healthy controls subjects. Secondarily, the investigators also want to: * Compare combined electrophysiological measurements with ERG and EEG between the two groups. * Identify relations between clinical, neuropsychological and circadian phenotypes in patients with BD and electrophysiological measurements measured with ERG and EEG. The main hypothesis of the investigators is that differences exist in the ERG and EEG measurements between subjects with BD and healthy subjects. Those differences could be identified as candidate markers for BD which, if confirmed in later studies, could be used in current practice to guide the management of patients with BD.
Bipolar disorders (BD) is a common, chronic and disabling psychiatric condition. In addition to being characterized by significant clinical heterogeneity, notable disturbances of sleep and cognitive function are frequently observed in all phases of the disease. Currently, there is no readily available biomarker in current clinical practice to help diagnose or predict the disease course. Thus, identification of biomarkers in BD is today a major challenge. In this context, the study of electrophysiological biomarkers based on electroretinogram (ERG) and electroencephalogram (EEG) measurements in BD seems highly promising. The BiMAR study aims to compare electrophysiological data measured with ERG and EEG between a group of euthymic patients with BD and a group of healthy control subjects. Secondarily, the investigators will also describe the existing potential relationship between clinical, sleep and neuropsychological phenotypes of patients and electrophysiological data. The BiMAR study is a comparative and monocentric study carried out at the Expert Center for BD in Nancy, France. In total, 70 euthymic adult patients with BD and 70 healthy control subjects will be recruited. Electrophysiological recordings with ERG and EEG will be performed with a virtual reality headset after a standardized clinical evaluation to all participants. Then, an actigraphic monitoring of 21 consecutive days will be carried out. At the end of this period a neuropsychological evaluation will be performed during a second visit. The primary outcome will be electrophysiological measurements with ERG flash and pattern. Secondary outcomes will be EEG data, sleep settings, clinical and neuropsychological assessments. For patients only, a complementary ancillary study, carried out at the University Hospital of Nancy, will be proposed to assess the retinal structure and microvascularization using Optical Coherence Tomography. Recruitment will begin in December 2021 and will continue until the end of June 2023. The BiMAR study will contribute to identifying candidate ERG electrophysiological markers for helping the diagnosis of BD and identify subgroups of patients with different clinical profiles. Eventually, this would allow earlier diagnosis and personalized therapeutic interventions.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
62
The Retinaute® is a portable medical device developed by BioSerenity, France, for performing flash and pattern ERG. It comes in the form of a virtual reality headset, which can be used in outpatient facilities. It is non-invasive and uses skin electrodes for the collection of parameters. ERG signals will be supplemented with 4 EEG channels, via cup electrodes applied to the skull and allowing the concomitant performance of an EEG.
Actigraphy is an ecological and non-invasive method allowing a reliable characterization of the sleep/wake cycle. It is a portable system for continuously measuring the motor activity of an individual and appreciating the alternation of activity periods (wakefulness) and rest periods (sleep). An actigraph (MotionWatch8®, CamNtech) looks like a wristwatch that will be worn continuously, by convention on the wrist of the non-dominant hand, over periods ranging from several days to several weeks (here 21 days). Actigraphy does not present a known risk.
The purpose of this assessment is to establish a cognitive profile for each participant. It uses a series of tests widely described in the literature and commonly used today.
The Spectral Domain Optical Coherence Tomography (SD-OCT) is a modern ocular imaging process using infrared radiation and allowing to obtain in a few seconds, and in a non-invasive way, images in section of the eye. The OCT-Angiography (OCT-A) module increments on the OCT. It can detect the movement of the blood elements from sequential SD-OCT slices taken at the same location of the retina and obtain a map of the retinal and choroidal vessels, without injection of fluorescent dye. The device used for both exams will be the OCT spectral RS 3000 Advance 2 + Angioscan (NIDEK, Gamagori, Japan). SD-OCT and OCT-A examinations are fast, painless, non-contact and last less than a minute. There is no particular risk.
Centre Psychothérapique de Nancy
Laxou, Nancy, France
Modification of amplitude measured with flash and pattern electroretinogram
amplitude in microvolt
Time frame: Day 0 (=day of inclusion)
Modification of implicite time measured with flash and pattern electroretinogram
implicite time in millisecond
Time frame: Day 0 (=day of inclusion)
Modification of amplitude measured with electroencephalogram
amplitude of the P100, N170 and N200 waves amplitude in microvolt
Time frame: Day 0 (=day of inclusion)
Modification of latency measured with electroencephalogram
latency of the P100, N170 and N200 waves latency in millisecond
Time frame: Day 0 (=day of inclusion)
Actigraphy
evaluation of sleep/wake cycles
Time frame: from Day1 to Day21
Sleep diary
self reported tool of sleeping and waking times
Time frame: from Day 1 to Day 21
Visual Object and Space Perception battery (VOSP)
test of visual cognition
Time frame: visit n ° 2 (=between Day 22 and Day 27)
California Verbal Learning Test (CVLT)
assessment of verbal episodic memory
Time frame: visit n ° 2 (=between Day 22 and Day 27)
Continuous Performance Task (CPT-III)
test of sustained attention
Time frame: visit n ° 2 (=between Day22 and Day27)
Verbal Fluency Task
test of verbal functioning
Time frame: visit n ° 2 (=between Day 22 and Day 27)
Test of Attention Assessment (TAP)
test of attentional performance
Time frame: visit n ° 2 (=between Day 22 and Day 27)
Montreal Cognitive Assessment (MoCA)
screening assessment for detecting cognitive impairment
Time frame: visit n ° 2 (=between Day 22 and Day 27)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.